Advanced search
Publication Cover
Expert Opinion on Drug Safety Volume 2, 2003 - Issue 3
Submit an article Journal homepage
31
Views
5
CrossRef citations to date
0
Altmetric
Review

The overall safety profile of currently available vaccines directed against infectious diseases

Robert M Jacobson Vaccine Research Group, Department of Pediatric and Adolescent Medicine, Department of Medicine, Mayo Building E931, Mayo Clinic, 200 First Street Southwest, Rochester, Minnesota 55905-0001, USA. [email protected]
,
Kim S Zabel Vaccine Research Group, Department of Pediatric and Adolescent Medicine, Department of Medicine, Mayo Building E931, Mayo Clinic, 200 First Street Southwest, Rochester, Minnesota 55905-0001, USA. [email protected]
&
Gregory A Poland Vaccine Research Group, Department of Pediatric and Adolescent Medicine, Department of Medicine, Mayo Building E931, Mayo Clinic, 200 First Street Southwest, Rochester, Minnesota 55905-0001, USA. [email protected]
Pages 215-223 | Published online: 03 Mar 2005

Bibliography

  • CENTERS FOR DISEASE CONTROL AND PREVENTION: Ten great public health achievements - United States, 1900-1999. MMWR (1999) 48:241–243.
  • CENTERS FOR DISEASE CONTROL AND PREVENTION: Vaccine Safeg,. Public Health Foundation, Waldorf, MD (2002):218–241.
  • SILVERS LE, ELLENBERG SS, WISE RE VARRICCHIO FE, MOOTREY GT, SALIVE ME: The epidemiology of fatalities reported to the vaccine adverse event reporting system 1990–1997. Pharmacoepidemiol. Drug Sat: (2001) 10:279–285.
  • •An excellent review of the deaths associated with vaccination as reported to the US CDC VAERS.
  • SILVERS LE, VARRICCHIO FE, ELLENBERG SS, KRUEGER CL, WISE RE SALIVE ME: Pediatric deaths reported after vaccination: the utility of information obtained from parents. Am. J. Prey. Med. (2002) 22:170–176.
  • GRIFFIN M, RAY W, LIVENGOOD J, SCHAFFNER W: Risk of sudden infant death syndrome after immunization with the diphtheria-tetanus-pertussis vaccine. N Engl. j Med. (1988) 319:618–623.
  • ESSERY S, RAZA M, ZORGANI A et al.: The protective effect of immunisation against diphtheria, pertussis and tetanus (DPT) in relation to sudden infant death syndrome. FEMS Inimunol. Med. Microbial. (1999) 25:183–192.
  • NIU M, SALIVE M, ELLENBERG S: Neonatal deaths after hepatitis B vaccine: the vaccine adverse event reporting system, 1991-1998. Arch. Pediatr. Adolesc. Med. (1999) 153:1279–1282.
  • JON VILLE-BERAA, AUTRET-LECA E, BARBEILLON F, PARIS-LLADO J: Sudden unexpected death in infants under 3 months of age and vaccination status - a case-control study. Br j Clin. Pharmacol. (2001) 51:271–276.
  • INSTITUTE OF MEDICINE: Adverse Events Associated with Childhood Vaccines. National Academy Press, Washington, DC (1994).
  • CHEN RT, DESTEFANO F, PLESS R, MOOTREY G, KRAMARZ P, HIBBS B: Challenges and controversies in immunization safety. Infect. Dis. Chi]. North Am. (2001) 15:21–39.
  • MCDONNELL WM, ASKARI FK: Immunization. JAMA (1997) 278:2000–2007.
  • ELLENBERG S: Safety considerations fornew vaccine development. Pharmacoepidemiol. Drug Sal: (2001) 10:411–415.
  • DITTMANN S: Vaccine safety: risk communication - a global perspective. Vaccine (2001) 19:2446–2456.
  • ADA G: Advances in immunology: vaccines and vaccination. N Engl. j Med. (2001) 345:1042–1053.
  • ZHOU W, POOL V, ISKANDER JK et al.: Surveillance for safety after immunization: Vaccine Event Report System (VAERS) - United States, 1991-2001. MMWR (2003) 52:1–24.
  • ••An outstanding review of the reports madeto the CDC VAERS regarding individual vaccine safety concerns.
  • BRAUN MM, PATRIARCA PA, ELLENBERG SS: Syncope after immunization. Arch. Pediatr. Adolesc. Med. (1997) 151:255–259.
  • •An excellent review of all the reports of syncope following vaccination as reported to the CDC VAERS.
  • ANONYMOUS: Anaphylaxis: statement oninitial management in nonhospital settings. Can. Med. Assoc. J. (1996) 154:1519–1522.
  • CENTERS FOR DISEASE CONTROL AND PREVENTION: Update: vaccine side effects, adverse reactions, contraindications, and precautions - recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR (1996) 45(RR-12):1–35.
  • ••An excellent summary of our current understanding of safety aspects of the routine vaccination schedule. 19.GEORGITIS JW, FASANO MB: Allergenic components of vaccines and avoidance of vaccination-related adverse events. Curr. Allergy Rep. (2001) 1:11–17.
  • •An encylopaedic listing of the components in vaccines that pose allergenic risks.
  • POOL V, BRAUN MM, KELSO JM et al.: Prevalence of anti-gelatin IgE antibodies in people with anaphylaxis after measles-mumps-rubella vaccine in the United States. Pediatrics (2002) 110:e71.
  • AMERICAN ACADEMY OF PEDIATRICS: Active Immunization. Pickering LK (Ed.), American Academy of Pediatrics, Elk Grove Village, IL (2000).
  • OVENS H: Anaphylaxis due to vaccinationin the office. Can. Med. Assoc. j (1986) 134:369–370.
  • US DEPARTMENT OF HEALTH AND HUMAN SERVICES PHS, CENTERS FOR DISEASE CONTROL AND PREVENTION: Adult immunization programs in nontraditional settings: quality standards and guidance for program evaluation: a report of the National Vaccine Advisory Committee. MMWR (2000) 49:1–14.
  • GELLIN BG, MAIBACH EW, MARCUSE EK: Do parents understand immunizations? A national telephone survey. Pediatrics (2000) 106:1097–1102.
  • •An important study that clarifies for providers and health care managers the issues that they face in vaccinating children.
  • OFFIT PA, QUARLES J, GERBER MA et al.: Addressing parents' concerns: do multiple vaccines overwhelm or weaken the infant's immune system? Pediatrics (2002) 110:648–649.
  • •An excellent review of a common parental concern regarding vaccination.
  • ENGLUND JA, SUAREZ CS, KELLY J, TATE DY, BALFOUR HH Jr: Placebo-controlled trial of varicella vaccine given with or after measles-mumps-rubella vaccine. j Pediatr. (1989) 114:37–44.
  • BRUNELL PA, NOVELLI VM, LIPTON SV, POLLOCK B: Combined vaccine against measles, mumps, rubella, and varicella. Pediatrics (1988) 81:779–784.
  • DEFOREST A, LONG SS, LISCHNER HW et al.: Simultaneous administration of measles-mumps-rubella vaccine with booster doses of diphtheria-tetanus-pertussis and poliovirus vaccines. Pediatrics (1988) 81:237–246.
  • GIAMMANCO G, LI VOLTI S, MAURO L et al.: Immune response to simultaneous administration of a recombinant DNA hepatitis B vaccine and multiple compulsory vaccines in infancy. Vaccine (1991) 9:747–750.
  • SHINEFIELD HR, BLACK SB, STAEHLE BO et al: Safety, tolerability and immunogenicity of concomitant injections in separate locations of M-M-R II, Varivaz and Tetramune in healthy children versus concomitant injections of M-M-R II and Tetramune followed six weeks later by Varivax. Pediatr. Infect. Dis. J. (1998) 17:980–985.
  • DASHEFSKY B, WALD E, GUERRA N, BYERS C: Safety, tolerability, and immunogenicity of concurrent administration of Haemophilus irilluenzae Type b conjugate vaccine (meningococcal protein conjugate) with either measles-mumps-rubella vaccine or diphtheria-tetanus-pertussis and oral poliovirus vaccines in 14- to 23-month-old infants. Pediatrics (1990) 85:682–689.
  • ANONYMOUS: Thimerosal in vaccines: a joint statement of the American Academy of Pediatrics and the Public Health Service. MMWR (1999) 48:563–565.
  • CLEMENTS CJ, BALL LK, BALL R, PRATT RD: Thiomersal in vaccines: is removal warranted? Drug Sal (2001) 24:567–574.
  • •An excellent review of the safety issues associated with this previously commonly-used mercury-containing preservative.
  • STRATTON K, GABLE A, SHETTY P, MCCORMICK M: Immunization Safely Review: Measles-Mumps-Rubella Vaccine and Autism Health Promotion and Disease Prevention. National Academy Press, Washington, DC (2001).
  • STRATTON K, ALMARIO DA, WIZEMANN TM, MCCORMICK MC: Immunization Safety Review: Vaccinations and Sudden Unexpected Death in Infancy National Academy Press, Washington, DC (2003).
  • COMMUNICABLE DISEASE SURVEILLANCE CENTRE: COVER programme: January to March 2001. Commun. Dis. Rep. CDR Wkly (2001) 11:6–8.
  • OWENS SR: Injection of confidence. The recent controversy in the UK has led to falling MMR vaccination rates. EMBO Rep. (2002) 3:406–409.
  • SPOONER MH: Measles outbreaks in UK linked to fears about MMR vaccine. Can. Med. Assoc. J. (2002) 166:1075.
  • POLAND GA, JACOBSON RM: Understanding those who do not understand: a brief review of the anti-vaccine movement. Vaccine (2001) :2440-2445.
  • POLAND GA, JACOBSON RM: Vaccine safety: injecting a dose of common sense. Mayo Clin. Proc. (2000) 75:135–139.
  • GELLIN BG, SCHAFFNER W: The risk ofvaccination - the importance of 'negative' studies. N Engl. j Med. (2001) 344:372–373.
  • ANONYMOUS: Vaccines - endangered species? Nat. Immunol (2002) 3:695.
  • CHEN R: Vaccine risks: real, perceived and unknown. Vaccine (1999) 17\(Suppl. 3):S41–S46.
  • PARKMAN PD: Making vaccination policy: the experience with rubella. Clin. Infect. Dis. (1999) 28\(Suppl. 2):5140–5146.
  • JACOBSON RM, ADEGBENRO A, PANKRATZ VS, POLAND GA: Adverse events and vaccination - the lack of power and predictability of infrequent events in prelicensure study. Vaccine (2001) 19:2428–2433.
  • ELLENBERG SS, BRAUN MM: Monitoring the safety of vaccines: assessing the risks. Drug Sal: (2002) 25:145–152.
  • BLACK S: Perspectives on the design andanalysis of prelicensure trials: bridging the gap to postlicensure studies. Clin. Infect. Dis. (2001) 33\(Suppl. 4):S323–S326.
  • DESTEFANO F AND THE VACCINE SAFETY DATALINK RESEARCH GROUP: The Vaccine Safety Datalink project. Pharmacoepidemiol Drug Sal (2001) 10:403–406.
  • CLARKSON A, INGLEBY E, CHOONARA I, BRYAN P, ARLETT P: A novel scheme for the reporting of adverse drug reactions. Arch. Dis. Child (2001) 84:337–339.
  • RENNELS MB: The rotavirus vaccine story: a clinical investigator's view. Pediatrics (2000) 106:123–125.
  • CENTERS FOR DISEASE CONTROL AND PREVENTION: Rotavirus vaccine for the prevention of rotavirus gastroenteritis among children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR (1999) 48:1–20.
  • HARRIS G: After vaccine's recall, regulators look for holes in the safety net. Wall St. (1999):B1,B4.
  • CENTERS FOR DISEASE CONTROL AND PREVENTION: Withdrawal of rotavirus vaccine recommendation. MMWR (1999) 48:1007.
  • GOLD M, GOODWIN H, BOTHAM S, BURGESS M, NASH M, KEMPE A: Revaccination of 421 children with a past history of an adverse vaccine reaction in a special immunisation service. Arch. Dis. Child. (2000) 83:128–131.
  • ANONYMOUS: Recommendations of the Advisory Committee on Immunization Practices (ACIP): use of vaccines and immune globulins for persons with altered immunocompetence. MMWR (1993) 42(RR-4):1–18.
  • DAVIS T, FREDRICKSON D, ARNOLD C et al.: Childhood vaccine risk/ benefit communication in private practice office settings: a national survey. Pediatrics (2001) 107:E17.
  • US DEPARTMENT OF HEALTH AND HUMAN SERVICES: Immunization and Infectious Diseases. US Government Printing Office, Washington, DC (2000):14–42.
  • YAWN BP, GAZZUOLA L, WOLLAN PC, KIM WR: Development and maintenance of a community-based hepatitis C registry. Am. I Manage. Care (2002) 8:253–261.
  • HEIJBEL H, JEFFERSON T: Vaccine safety - improving monitoring. Vaccine (2001) 19:2457–2460.
  • YAWN BP, EDMONSON L, HUBER L, POLAND GA, JACOBSON RIVI, JACOBSEN SJ: The impact of a simulated immunization registry on perceived childhood immunization status. Ain. J. Manage. Care (1998) 4:185–192.
  • WOLFE S: Vaccine information statementsin the pediatric office. Pediatr. Ann. (2001) 30:416–417.
  • JACOBSON RIVI, ZABEL KS, POLAND GA: The challenge of vaccine safety. Seinfri. Pediatr. Infect. Dis. (2002) 13:215–220.
  • POLAND GA, MURRAY D, BONILLA-GUERRERO R: Science, medicine, and the future: new vaccine development. Br. Med. j (2002) 324:1315–1319.
  • ANDRE FE: The future of vaccines, immunisation concepts and practice. Vaccine (2001) 19:2206–2209.
  • US DEPARTMENT OF HEALTH AND HUMAN SERVICES PHS, CENTERS FOR DISEASE CONTROL AND PREVENTION: Guide to contraindications to childhood vaccinations, 2000 (2000). Report.

Websites

  • http://www.cdc.gov/nip/publications/ 6mishome.htm CENTERS FOR DISEASE CONTROL AND PREVENTION: Six common misconceptions about vaccination and how to respond to them (2002).
  • •A useful publication for vaccine providers to use in educating vaccine recipients. The NIP site on the web is perhaps the most important electronic resource for vaccine providers and healthcare managers.
  • http://www.cdc.gov/nip/vacsafe/concerns/ thimerosal/joint_statement_00.htm CENTERS FOR DISEASE CONTROL AND PREVENTION: Joint statement concerning removal of thimerosal from vaccines (2002).
  • http://www.aap.org
  • •A very useful electronic resource for vaccine providers and healthcare managers.
  • http://www.immunize.org
  • •A very useful electronic resource for vaccine providers and healthcare managers.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.